Aktis Oncology prices upsized US IPO at $18 per share
Tweet
Share
E-mail
People exit the New York Stock Exchange (NYSE) on Wall Street in New York City, U.S., January 6, 2026. REUTERS/Brendan McDermid
Jan 8 (Reuters) - Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
Aktis is targeting a valuation of up to $945.4 million in the IPO.
(Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teen pleads guilty to killing four in 2024 U.S. school shooting
- Suicide bombing in Pakistan kills 15, including 12 soldiers, army says
- Netanyahu to meet with Trump in Washington on Tuesday, PM's office says
Create E-mail Alert Related Categories
ReutersRelated Entities
IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
